Year: 2018
Type: article
Abstract: Significance In HER2 -amplified breast cancers, HER2 inhibitors have been very successful as adjuvant therapy but not as monotherapy. Here, we demonstrate that coamplification of a HER2 intronic miRNA causes intrinsic resistance to HER2 inhibitors by indirectly down-regulating the pro-apoptotic NOXA. Importantly, coinhibition with MCL-1 inhibitors overcomes this resistance.
Authors: Konstantinos V. Floros, Timothy L. Lochmann, Bin Hu, Carles Monterrubio, Mark T. Hughes, Jason D. Wells, Cristina Bernadó Morales, Maninderjit S. Ghotra, Carlotta Costa, Andrew J. Souers, Sosipatros A. Boikos, Joel D. Leverson, Ming Tan, Violeta Serra, Jennifer E. Koblinski, Joaquin Arribas, Aleix Prat, Laia Paré, Todd W. Miller, Mikhail G. Dozmorov, Hisashi Harada, Brad E. Windle, Maurizio Scaltriti, Anthony C. Faber
Institutions: Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Dartmouth College, Dartmouth Cancer Center, Centro de Investigación Biomédica en Red de Cáncer, Vall d'Hebron Institute of Oncology, Harvard University, Massachusetts General Hospital, AbbVie (United States), USA Mitchell Cancer Institute, University of South Alabama, Institució Catalana de Recerca i Estudis Avançats, Universitat Autònoma de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: National Cancer Institute
Awards: Assessing BIM expression as a cause and marker for resistance to targeted therapi, Timing is everything: applications in precision oncology for ER+ breast cancer, The possible role of the novel Akt 3 R247C mutation in opposing to anti-HER2 ther, Cancer Center Support Grant, A precision medicine basis for estrogen therapy for advanced breast cancer, Massey Cancer Center - Cancer Center Support Grant
OpenAlex ID: W2791452587